Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN2 | P17655 | 10/20 | 0.56 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.42 |
| ▸ | MMP1 | P03956 | 5/20 | 0.40 |
| ▸ | MMP2 | P08253 | 5/20 | 0.40 |
| ▸ | MMP3 | P08254 | 5/20 | 0.40 |
| ▸ | MMP7 | P09237 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12943215 | 0.90 | CAPN2 (0.54) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL12943095 | 0.85 | CAPN2 (0.53) | CAPN2MMP1MMP2MMP3MMP7 | |
| SCHEMBL12943113 | 0.82 | CAPN2 (0.51) | CAPN2MMP1MMP2MMP3MMP7 | |
| SCHEMBL12943087 | 0.78 | CAPN2 (0.57) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL12943105 | 0.78 | CAPN2 (0.56) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL931991 | 0.77 | CAPN2 (0.77) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL931561 | 0.75 | CAPN2 (0.56) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL930611 | 0.73 | CAPN2 (1.00) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL8208872 | 0.73 | CAPN2 (1.00) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL931593 | 0.72 | CAPN2 (0.57) | CAPN2MMP1MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | UNIVERSITY OF CANTERBURY (NZ) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | CAPN2 4/4885CPB2 36/4885MMP1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.